RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

NCT01127542 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class

Stopped Potential safety issue of second primary malignancies in patients treated with lenalidomide.

Conditions

Interventions

Sponsor

The Christie NHS Foundation Trust

Collaborators